Navigation Links
Kensey Nash Corporation Announces Its Third Quarter 2009 Earnings Release Date and Teleconference
Date:4/9/2009

EXTON, Pa., April 9 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it will release its earnings results for its third quarter ended March 31, 2009 at 7:30 A.M. Eastern Time on Wednesday, April 22, 2009.

Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Wednesday, April 22, 2009 at 9:00 A.M. Eastern Time.

To participate in the teleconference call, dial 1-612-234-9959. The teleconference call will also be available for replay starting Wednesday, April 22, 2009 at 11:00 A.M. Eastern Time through Wednesday, April 29, 2009 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 995293.

Individuals interested in listening to the teleconference may also do so over the Internet at www.kenseynash.com. To listen to the live teleconference call, please go to the www.kenseynash.com website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the www.kenseynash.com website and may be accessed following the teleconference.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processin
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kensey Nash Announces 600,000 Share Stock Repurchase Program
2. Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
3. Kensey Nash Announces Appointment of Chief Financial Officer
4. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
5. Kensey Nash Announces Director Resignation
6. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
7. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
8. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
9. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
10. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
11. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Study 3A Oil speculators dominate open interest in oil futures 9713 1Study 3A Oil speculators dominate open interest in oil futures 9713 2Study 3A Oil speculators dominate open interest in oil futures 9713 3Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 1Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 2Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 3IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 1IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 2IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 3